Levodopa/Carbidopa/Entacapone Viatris

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Viatris, is an antiparkinson agent presented as a combination tablet for oral use. It treats Parkinson's disease in adults by enhancing central dopaminergic activity and stabilising motor function.

GNH USA supplies Levodopa/Carbidopa/Entacapone Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used within the antiparkinson therapeutic class to manage motor symptoms and fluctuations in Parkinson's disease.

- Parkinson's disease (motor fluctuations): reduces OFF periods and improves overall motor control. - Parkinson's disease (early stage): enhances response to levodopa and delays progression of motor symptoms. - Parkinson's disease (advanced stage): provides more consistent dopaminergic stimulation, helping to maintain daily activities.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions. Patients should be monitored for both common and serious events.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dizziness - Insomnia - Dyskinesia

Serious or Rare Side Effects: - Severe hypotension or syncope - Hallucinations or psychosis - Neuroleptic malignant‑like syndrome - Agranulocytosis or severe leukopenia - Hepatic dysfunction - Severe allergic reactions (e.g., Stevens‑Johnson syndrome)

Use of this combination requires careful clinical oversight to minimise risks.

- Dose titration: adjust gradually under physician supervision. - Cardiovascular monitoring: watch for orthostatic hypotension and arrhythmias. - Psychiatric assessment: monitor for hallucinations, confusion, or mood changes. - Renal/hepatic impairment: consider dose reduction or increased monitoring. - Drug interactions: review all concomitant medications for potential conflicts. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapone interacts with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - MAO‑B inhibitors (e.g., selegiline, rasagiline): may cause severe hypertension. - Antihypertensive agents (especially alpha‑blockers): can exacerbate hypotension. - Dopamine antagonists (typical antipsychotics): reduce therapeutic effect. - Certain anti‑emetics (e.g., metoclopramide): may diminish levodopa efficacy.

Moderate Interactions (Monitor Closely): - Other COMT inhibitors: additive effect on levodopa levels. - CNS depressants (e.g., benzodiazepines): may increase sedation. - Diuretics: may potentiate orthostatic hypotension. - Iron or calcium supplements: can impair levodopa absorption. - SSRIs or SNRIs: monitor for serotonin syndrome when combined with MAO‑B inhibitors.